M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Dyadic Yoga Intervention for the Improvement of Healthcare Utilization and Quality of Life in Patients With Head and Neck Cancer Undergoing Chemoradiation and Their Caregivers

Not Applicable

Recruiting

Conditions: Head and Neck Carcinoma

Interventions: Other: Best Practice
Other: Exercise Intervention
Other: Questionnaire Administration

First Posted Date: 2021-05-18

Last Posted Date: 2024-12-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 400

Registration Number: NCT04890834

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies

Recruiting

Conditions: Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Other: Data Capture
Other: Electronic Medical Record

First Posted Date: 2021-05-17

Last Posted Date: 2024-10-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT04888338

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

Phase 2

Recruiting

Conditions: Metastatic Malignant Solid Neoplasm
Locally Advanced Malignant Solid Neoplasm

Interventions: Drug: Larotrectinib Sulfate

First Posted Date: 2021-05-10

Last Posted Date: 2024-11-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT04879121

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma

Phase 1

Active, not recruiting

Conditions: Clinical Stage I Cutaneous Melanoma AJCC v8
Clinical Stage IA Cutaneous Melanoma AJCC v8
Clinical Stage IIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIC Cutaneous Melanoma AJCC v8
Pathologic Stage I Cutaneous Melanoma AJCC v8
Pathologic Stage IB Cutaneous Melanoma AJCC v8
Pathologic Stage IIA Cutaneous Melanoma AJCC v8
Clinical Stage IB Cutaneous Melanoma AJCC v8
Clinical Stage II Cutaneous Melanoma AJCC v8

Interventions: Drug: Cefazolin
Procedure: Resection

First Posted Date: 2021-05-06

Last Posted Date: 2024-11-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT04875728

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Patient Reported Symptom Control With THC or CBD Use

Recruiting

Conditions: Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm
Cancer-Associated Pain

Interventions: Other: Electronic Health Record Review
Other: Questionnaire Administration

First Posted Date: 2021-05-06

Last Posted Date: 2024-03-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 250

Registration Number: NCT04875286

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

Phase 1

Completed

Conditions: Recurrent Acute Myeloid Leukemia
Hematopoietic and Lymphoid Cell Neoplasm
Recurrent Myelodysplastic Syndrome
Recurrent Acute Biphenotypic Leukemia
Refractory Acute Biphenotypic Leukemia
Refractory Acute Myeloid Leukemia
Refractory Myelodysplastic Syndrome

Interventions: Drug: Omacetaxine Mepesuccinate
Drug: Venetoclax

First Posted Date: 2021-05-05

Last Posted Date: 2024-10-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT04874194

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Tegavivint for the Treatment of Relapsed or Refractory Leukemia

Phase 1

Active, not recruiting

Conditions: Recurrent Leukemia
Refractory Leukemia

Interventions: Drug: Decitabine
Drug: Tegavivint

First Posted Date: 2021-05-05

Last Posted Date: 2024-10-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 9

Registration Number: NCT04874480

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Patient Reported Outcome Post Radiation Therapy or Chemoradiotherapy Patient Care in Patients With Oropharyngeal Cancer

Active, not recruiting

Conditions: Oropharyngeal Carcinoma

Interventions: Other: Electronic Health Record Review
Other: Questionnaire Administration

First Posted Date: 2021-05-05

Last Posted Date: 2024-07-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 77

Registration Number: NCT04874493

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial

Not Applicable

Recruiting

Conditions: Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma

Interventions: Procedure: Biospecimen Collection
Other: Follow-Up

First Posted Date: 2021-05-04

Last Posted Date: 2024-03-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT04872413

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy

Recruiting

Conditions: Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Recurrent High Grade B-Cell Lymphoma

Interventions: Other: Electronic Health Record Review

First Posted Date: 2021-05-04

Last Posted Date: 2023-11-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 150

Registration Number: NCT04870853

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Home Terms & Conditions Privacy Policy